切换至 "中华医学电子期刊资源库"
高级检索
中华诊断学电子杂志

中华诊断学电子杂志 ›› 2019, Vol. 07 ›› Issue (03) : 151 -154. doi: 10.3877/cma.j.issn.2095-655X.2019.03.003

所属专题： 文献；

肿瘤心脏病诊治

氟尿嘧啶治疗致急性冠状动脉综合征的诊断学特征并文献复习
王春晖1, 李静1, 吴薇1, 林瑾仪2, 许宇辰3, 吕迁洲1, 程蕾蕾3,†()   
  1. 1. 200032　上海，复旦大学附属中山医院药剂科
    2. 200032　上海，复旦大学附属中山医院心内科
    3. 200032　上海，复旦大学附属中山医院心脏超声诊断科
  • 收稿日期:2018-11-05 出版日期:2019-08-26
  • 通信作者: 程蕾蕾
  • 基金资助:
    国家自然科学基金面上项目(81771840); 上海市卫生系统优秀人才培养计划(2017BR027)

Diagnostic features and literature review of acute coronary syndrome induced by fluorouracil

Chunhui Wang1, Jing Li1, Wei Wu1, Jinyi Lin2, Yuchen Xu3, Qianzhou Lyu1, Leilei Cheng3,†()   

  1. 1. Department of Pharmacy, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China
    2. Department of Cardiology, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China
    3. Department of Echocardiography, Zhongshan Hospital Affiliated to Fudan University, Shanghai 200032, China
  • Received:2018-11-05 Published:2019-08-26
  • Corresponding author: Leilei Cheng
  • About author:
    Corresponding author: Cheng Leilei, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王春晖, 李静, 吴薇, 林瑾仪, 许宇辰, 吕迁洲, 程蕾蕾. 氟尿嘧啶治疗致急性冠状动脉综合征的诊断学特征并文献复习[J]. 中华诊断学电子杂志, 2019, 07(03): 151-154.

Chunhui Wang, Jing Li, Wei Wu, Jinyi Lin, Yuchen Xu, Qianzhou Lyu, Leilei Cheng. Diagnostic features and literature review of acute coronary syndrome induced by fluorouracil[J]. Chinese Journal of Diagnostics(Electronic Edition), 2019, 07(03): 151-154.

目的

探讨氟尿嘧啶治疗致急性冠状动脉综合征的诊断学特征。

方法

回顾性分析1例因结肠癌于复旦大学附属中山医院肿瘤科治疗，氟尿嘧啶化疗后出现急性冠状动脉综合征患者的临床资料，并复习相关文献。

结果

患者男性，60岁，为合并冠心病行经皮冠状动脉介入治疗的结肠癌患者，行辅助化疗FOLFOX(氟尿嘧啶、亚叶酸钙、奥沙利铂)方案，第1周期第14天出现胸闷、持续性胸部隐痛，平卧不能，端坐呼吸，气稍促。血清心肌肌钙蛋白T(cTnT)(0.687 μg/L)，氨基末端利钠肽前体(NT-proBNP)(7 128 ng/L)水平均显著升高；心电图呈持续性心肌缺血改变；肺动脉CT血管造影未见明确栓塞征象。排除其他病理因素和药物因素可能，考虑为氟尿嘧啶治疗致急性冠状动脉综合征。经对症支持治疗后心肌细胞损伤标志物水平逐渐下降，患者未再诉胸闷、胸痛症状。改予TOMOX(奥沙利铂、雷替曲塞)方案，化疗期间和化疗后定期随访，心电图、经胸超声心动图较之前无明显变化，cTnT水平逐渐降低至正常值。

结论

氟尿嘧啶化疗患者应密切监测其心脏毒性如急性冠状动脉综合征的发生，保障患者化疗顺利进行。

关键词: 氟尿嘧啶, 化疗方法，辅助, 急性冠状动脉综合征, 冠心病, 结肠肿瘤
Objective

To explore the diagnostic features of acute coronary syndrome induced by fluorouracil.

Methods

A case of acute coronary syndrome after fluorouracil chemotherapy who was treated for colon cancer in the oncology department of Zhongshan Hospital Affiliated to Fudan University was retrospectively analyzed, the relevant literatures were reviewed.

Results

A 60-year-old male colon cancer patient combined with coronary heart disease who underwent percutaneous coronary intervention accepted the first cycle adjuvant chemotherapy FOLFOX (fluorouracil, calcium folinate, oxaliplatin) regimen. On the 14th day after chemotherapy, he developed chest tightness, persistent chest pain, inability to lie flat, sitting breathing and shortness of breath. Both serum cardiac troponin (cTnT) level (0.687 μg/L) and N-terminal pro B-type natriuretic (NT-proBNP) level (7 128 ng/L) increased significantly, ECG revealed persistent myocardial ischemia changes and pulmonary CTA showed no definite embolism signs. Excluding other pathological and drug factors, acute coronary syndrome caused by fluorouracil was considered. After the symptomatic supportive treatment, the levels of cTnT and NT-proBNP reduced gradually while the patient no longer complained of chest tightness or chest pain. The surveillance of ECG and TTE during and after TOMOX(oxaliplatin, raltitrexed) regimen had no difference and the level of cTnT decreased to the normal.

Conclusion

Patients receiving fluorouracil should be monitored carefully of drug-induced cardiotoxicity, such as acute coronary syndrome, to ensure the smooth progress of chemotherapy.

Key words: Fluorouracil, Chemotherapy, adjuvant, Acute coronary syndrome, Coronary heart disease, Colon cancer
表1 结肠癌患者入院后血液主要研究指标变化情况
指标 入院后第1天 入院后第12天 入院后第17天 入院后第31天 入院后第74天 入院后第187天
心肌肌钙蛋白T(μg/L) 0.687 0.238 0.157 0.051 0.030 0.024
氨基末端利钠肽前体(ng/L) 7 128 4 933 2 487 2 278 1 181 1 118
红细胞计数(×1012/L) 2.81 1.47 1.36 1.41 3.49 3.63
血红蛋白(g/L) 83 49 52 60 127 121
[1]
Deboever G, Hiltrop N, Cool M，et al.Alternative treatment options in colorectal cancer patients with 5-fluorouracil-or capecitabine-induced cardiotoxicity[J]．Clin Colorectal Cancer，2013，12(1):8-14.
[2]
Kwakman JJ, Simkens LH, Mol L，et al.Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer：a retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group[J] .Eur J Cancer，2017(76):93-99.
[3]
Polk A, Vistisen K, Vaage-Nilsen M，et al.A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity[J]．BMC Pharmacol Toxicol，2014，15(1):47.
[4]
Alter P, Herzum M, SoufiI M，et al.Cardiotoxicity of 5-fluorouracil[J]．Cardiovasc Hematol Agents Med Chem，2006，4(1):1-5.
[5]
Sorrentino MF, Kim J, Foderaro AE，et al.5-fluorouracil induced cardiotoxicity: review of the literature[J]．Cardiol J，2012，19(5):453-458.
[6]
Polk A, Vaage-Nilsen M, Vistisen K，et al.Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine：a systematic review of incidence，manifestations and predisposing factors[J]．Cancer Treat Rev，2013，39(8):974-984.
[7]
Meydan N, Kundak I, Yavuzsen T, et al.Cardiotoxicity of de Gramont′s regimen：incidence，clinical characteristics and long-term follow-up[J]．Jpn J Clin Oncol，2005，35(5):265-270.
[8]
Saif MW, Shah MM, Shah AR.Fluoropyrimidine-associated cardiotoxicity：revisited[J]．Expert Opin Drug Saf，2009，8(2):191-202.
[9]
Kosmas C, Kallistratos MS, Kopterides P, et al.Cardiotoxicity of fluoropyrimidines in different schedules of administration：a prospective study[J]．J Cancer Res Clin Oncol，2008，134(1):75-82.
[10]
Khan MA, Masood N, Husain N, et al.A retrospective study of cardiotoxicities induced by 5-fluouracil (5-FU) and 5-FU based chemotherapy regimens in Pakistani adult cancer patients at Shaukat Khanum Memorial Cancer Hospital & Research Center[J]．J PakMed Assoc，2012，62(5):430-434.
[11]
林果为，王吉耀，葛均波．实用内科学 [M].15版．北京：人民卫生出版社，2017：975-978.
[12]
Yamada Y, Hamaguchi T, Goto M，et al.Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1，a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine，as compared with protracted venous infusion of 5-fluorouracil[J]．Br J Cancer，2003，89(5):816-820.
[13]
Sara JD, Kaur J, Khodadadi R，et al.5-fluorouracil and cardiotoxicity：a review[J]．Ther Adv Med Oncol，2018(10):1758835918780140.
[1] 李志伟, 向琪, 彭胜男, 郭玲, 孙贱根, 杨川. 右美托咪定与曲马多分别复合罗哌卡因在全麻下结肠癌根治术中的应用[J]. 中华普通外科学文献(电子版), 2023, 17(03): 182-185.
[2] 燕速, 霍博文, 徐惠宁. 4K荧光腹腔镜扩大右半结肠CME+D3根治术及No.206、No.204组淋巴结清扫术[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 14-14.
[3] 姚宏伟, 魏鹏宇, 高加勒, 张忠涛. 不断提高腹腔镜右半结肠癌D3根治术的规范化[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 1-4.
[4] 杜晓辉, 崔建新. 腹腔镜右半结肠癌D3根治术淋巴结清扫范围与策略[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 5-8.
[5] 周岩冰, 刘晓东. 腹腔镜右半结肠癌D3根治术消化道吻合重建方式的选择[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 9-13.
[6] 徐伯麒, 陶亮, 章帆, 毛忠琦. 结肠癌患者淋巴结转移预测模型的建立[J]. 中华普外科手术学杂志(电子版), 2023, 17(04): 393-397.
[7] 符谨诚, 李彦庆, 王亮, 邹科见. 巨大结肠脂肪瘤伴急性肠套叠一例并文献复习[J]. 中华普外科手术学杂志(电子版), 2023, 17(03): 347-348.
[8] 蓝冰, 王怀明, 王辉, 马波. 局部晚期结肠癌膀胱浸润的研究进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 505-511.
[9] 侯文运, 刘恒昌, 窦利州, 陈海鹏, 郑朝旭, 王贵齐, 王锡山. 腹部无辅助切口内镜引导下取标本的腹腔镜辅助右半结肠癌根治术（保留回盲部）（附视频）[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 436-440.
[10] 唐新, 刁德昌, 廖伟林, 林佳鑫, 汪佳豪, 李文娟, 谢嘉欣, 敖琳, 李洪明, 易小江, 卢新泉, 冯晓创. 保留神经的鞘外游离技术在腹腔镜右半结肠癌D3根治术中的近远期疗效分析：基于倾向性评分匹配的回顾性队列研究[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 372-380.
[11] 陈润芝, 杨东梅, 徐慧婷. 信迪利单抗联合索凡替尼后线治疗MSS型BRAF突变的转移性结肠癌：个案报道并文献复习[J]. 中华结直肠疾病电子杂志, 2023, 12(05): 431-435.
[12] 常远, 白杨, 王文秀, 孙振强, 周全博, 崔雯铭, 王玉行, 袁维堂, 胡军红. 电子结肠镜辅助经结肠取标本手术在结肠肿瘤中的临床应用分析[J]. 中华结直肠疾病电子杂志, 2023, 12(03): 196-199.
[13] 邓振汝, 林树文, 吕泽坚, 郑佳彬, 廖乾超, 冯伙伦, 吴德庆, 王俊江, 李勇. 横结肠切除与扩大结肠切除治疗横结肠癌疗效比较[J]. 中华结直肠疾病电子杂志, 2023, 12(03): 214-220.
[14] 路继永, 王帅, 张成仁, 吴德望, 杨熊飞. 腹腔镜右半结肠切除应用现状[J]. 中华结直肠疾病电子杂志, 2023, 12(03): 221-227.
[15] 颜凡辉, 赵明俐, 李颖, 郭方明, 詹景冬, 赵英杰, 王阳, 张艳芬, 赵笑梅. 急性冠脉综合征患者冠脉血管病变程度与血清TNF-α、VEGF水平相关性研究[J]. 中华诊断学电子杂志, 2023, 11(03): 158-164.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号